context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The total intrinsic value of options (difference between price per share as of the exercise date and the exercise price, times the number of options outstanding) exercised during the years ended December 31, 2024, 2023 and 2022 was $ 0.1 million, $ 33.7 million and $ 16.2 million, respectively. | text | 33.7 | monetaryItemType | text: <entity> 33.7 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options (difference between price per share as of the exercise date and the exercise price, times the number of options outstanding) exercised during the years ended December 31, 2024, 2023 and 2022 was $ 0.1 million, $ 33.7 million and $ 16.2 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of options (difference between price per share as of the exercise date and the exercise price, times the number of options outstanding) exercised during the years ended December 31, 2024, 2023 and 2022 was $ 0.1 million, $ 33.7 million and $ 16.2 million, respectively. | text | 16.2 | monetaryItemType | text: <entity> 16.2 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options (difference between price per share as of the exercise date and the exercise price, times the number of options outstanding) exercised during the years ended December 31, 2024, 2023 and 2022 was $ 0.1 million, $ 33.7 million and $ 16.2 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. | text | 0.0 | monetaryItemType | text: <entity> 0.0 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. | text | 17.4 | monetaryItemType | text: <entity> 17.4 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. | text | 0.0 | monetaryItemType | text: <entity> 0.0 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to stock options was $ 0.0 million, $ 0.2 million and $ 17.4 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 0.0 million, $ 0.0 million and $ 0.1 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
As of December 31, 2024, there was no unrecognized compensation cost related to stock options that is expected to be recognized as an expense by the Company in the future. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, there was no unrecognized compensation cost related to stock options that is expected to be recognized as an expense by the Company in the future. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions |
For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. | text | 0.0 | monetaryItemType | text: <entity> 0.0 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. </context> | us-gaap:ProceedsFromStockOptionsExercised |
For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. | text | 32.6 | monetaryItemType | text: <entity> 32.6 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. </context> | us-gaap:ProceedsFromStockOptionsExercised |
For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. | text | 30.5 | monetaryItemType | text: <entity> 30.5 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. </context> | us-gaap:ProceedsFromStockOptionsExercised |
For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. | text | 24.7 | monetaryItemType | text: <entity> 24.7 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. | text | 6.7 | monetaryItemType | text: <entity> 6.7 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the Company received cash from the exercise of stock option awards of $ 0.0 million, $ 32.6 million and $ 30.5 million, respectively. Our realized tax benefit from stock options exercised or cancelled and automatically converted into the right to receive an amount in cash in connection with the Merger for the years ended December 31, 2024, 2023 and 2022 was $ 24.7 million, $ 6.7 million and $ 2.5 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. | text | 4.5 | monetaryItemType | text: <entity> 4.5 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. | text | 16.2 | monetaryItemType | text: <entity> 16.2 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. | text | 10.2 | monetaryItemType | text: <entity> 10.2 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. | text | 1.1 | monetaryItemType | text: <entity> 1.1 </entity> <entity type> monetaryItemType </entity type> <context> Total compensation expense relating to restricted stock awards was $ 4.5 million, $ 16.2 million and $ 10.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our recognized tax benefit from this expense for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.2 million and $ 1.1 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The total intrinsic value of restricted stock which vested during each of the years ended December 31, 2024, 2023 and 2022 was $ 27.7 million, $ 7.9 million and $ 9.5 million, respectively. | text | 27.7 | monetaryItemType | text: <entity> 27.7 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of restricted stock which vested during each of the years ended December 31, 2024, 2023 and 2022 was $ 27.7 million, $ 7.9 million and $ 9.5 million, respectively. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
The total intrinsic value of restricted stock which vested during each of the years ended December 31, 2024, 2023 and 2022 was $ 27.7 million, $ 7.9 million and $ 9.5 million, respectively. | text | 7.9 | monetaryItemType | text: <entity> 7.9 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of restricted stock which vested during each of the years ended December 31, 2024, 2023 and 2022 was $ 27.7 million, $ 7.9 million and $ 9.5 million, respectively. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
The total intrinsic value of restricted stock which vested during each of the years ended December 31, 2024, 2023 and 2022 was $ 27.7 million, $ 7.9 million and $ 9.5 million, respectively. | text | 9.5 | monetaryItemType | text: <entity> 9.5 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of restricted stock which vested during each of the years ended December 31, 2024, 2023 and 2022 was $ 27.7 million, $ 7.9 million and $ 9.5 million, respectively. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
s. The 2020 PSU awards vested on February 3, 2023. For the year ended December 31, 2022, the Company recorded the required share-based award expense related to the awards of $ 9.8 million, based on its assessment of the probability for achievement of the performance targets. | text | 9.8 | monetaryItemType | text: <entity> 9.8 </entity> <entity type> monetaryItemType </entity type> <context> s. The 2020 PSU awards vested on February 3, 2023. For the year ended December 31, 2022, the Company recorded the required share-based award expense related to the awards of $ 9.8 million, based on its assessment of the probability for achievement of the performance targets. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
For the year ended December 31, 2023 and 2022, the Company recorded the required share-based award expense related to the awards of $ 7.1 million and $ 23.7 million, respectively, based on its assessment of the probability for achievement of the performance targets. | text | 7.1 | monetaryItemType | text: <entity> 7.1 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023 and 2022, the Company recorded the required share-based award expense related to the awards of $ 7.1 million and $ 23.7 million, respectively, based on its assessment of the probability for achievement of the performance targets. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
For the year ended December 31, 2023 and 2022, the Company recorded the required share-based award expense related to the awards of $ 7.1 million and $ 23.7 million, respectively, based on its assessment of the probability for achievement of the performance targets. | text | 23.7 | monetaryItemType | text: <entity> 23.7 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023 and 2022, the Company recorded the required share-based award expense related to the awards of $ 7.1 million and $ 23.7 million, respectively, based on its assessment of the probability for achievement of the performance targets. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
For the year to date period through April 19, 2024, the Company concluded that achievement of any of the performance metrics had not yet met the level of probability required to record compensation expense and as such, no expense related to these awards was recognized. As a part of the Merger, all PSUs, whether vested or unvested, outstanding as of immediately prior to the closing of the Merger were fully vested, cancelled and automatically converted into the right to receive an amount in cash. As such, no share-based compensation expense related to these awards was recognized. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> For the year to date period through April 19, 2024, the Company concluded that achievement of any of the performance metrics had not yet met the level of probability required to record compensation expense and as such, no expense related to these awards was recognized. As a part of the Merger, all PSUs, whether vested or unvested, outstanding as of immediately prior to the closing of the Merger were fully vested, cancelled and automatically converted into the right to receive an amount in cash. As such, no share-based compensation expense related to these awards was recognized. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. | text | 0.55 | perShareItemType | text: <entity> 0.55 </entity> <entity type> perShareItemType </entity type> <context> In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. </context> | us-gaap:CommonStockDividendsPerShareCashPaid |
In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. | text | 2.10 | perShareItemType | text: <entity> 2.10 </entity> <entity type> perShareItemType </entity type> <context> In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. </context> | us-gaap:CommonStockDividendsPerShareCashPaid |
In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. | text | 2.00 | perShareItemType | text: <entity> 2.00 </entity> <entity type> perShareItemType </entity type> <context> In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. </context> | us-gaap:CommonStockDividendsPerShareCashPaid |
In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. | text | 82.6 | monetaryItemType | text: <entity> 82.6 </entity> <entity type> monetaryItemType </entity type> <context> In each of the years ended December 31, 2024, 2023 and 2022, we paid dividends of $ 0.55 per share (prior to the Merger), $ 2.10 per share, and $ 2.00 per share per share, respectively. In 2024 subsequent to the Merger, we paid dividends of $ 82.6 million. </context> | us-gaap:PaymentsOfDividendsCommonStock |
Our senior notes are fully and unconditionally guaranteed on an unsecured basis, jointly and severally, by the following subsidiaries (collectively, the "Guarantor Subsidiaries"), which are 100 %-owned subsidiaries of the Company. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> Our senior notes are fully and unconditionally guaranteed on an unsecured basis, jointly and severally, by the following subsidiaries (collectively, the "Guarantor Subsidiaries"), which are 100 %-owned subsidiaries of the Company. </context> | us-gaap:MinorityInterestOwnershipPercentageByParent |
As the combined assets, liabilities and results of operations of M.D.C. Holdings, Inc. and the Guarantor Subsidiaries (the “Obligor Group”) are not materially different from those in the homebuilding section of our consolidated balance sheets and consolidated statements of operations and comprehensive income, separate summarized financial information of the Obligor Group has not been included. As of December 31, 2024 and 2023 amounts due from non-guarantor subsidiaries to the Obligor Group totaled $ 34.8 million and $ 39.6 million, respectively. | text | 34.8 | monetaryItemType | text: <entity> 34.8 </entity> <entity type> monetaryItemType </entity type> <context> As the combined assets, liabilities and results of operations of M.D.C. Holdings, Inc. and the Guarantor Subsidiaries (the “Obligor Group”) are not materially different from those in the homebuilding section of our consolidated balance sheets and consolidated statements of operations and comprehensive income, separate summarized financial information of the Obligor Group has not been included. As of December 31, 2024 and 2023 amounts due from non-guarantor subsidiaries to the Obligor Group totaled $ 34.8 million and $ 39.6 million, respectively. </context> | us-gaap:OtherLiabilities |
As the combined assets, liabilities and results of operations of M.D.C. Holdings, Inc. and the Guarantor Subsidiaries (the “Obligor Group”) are not materially different from those in the homebuilding section of our consolidated balance sheets and consolidated statements of operations and comprehensive income, separate summarized financial information of the Obligor Group has not been included. As of December 31, 2024 and 2023 amounts due from non-guarantor subsidiaries to the Obligor Group totaled $ 34.8 million and $ 39.6 million, respectively. | text | 39.6 | monetaryItemType | text: <entity> 39.6 </entity> <entity type> monetaryItemType </entity type> <context> As the combined assets, liabilities and results of operations of M.D.C. Holdings, Inc. and the Guarantor Subsidiaries (the “Obligor Group”) are not materially different from those in the homebuilding section of our consolidated balance sheets and consolidated statements of operations and comprehensive income, separate summarized financial information of the Obligor Group has not been included. As of December 31, 2024 and 2023 amounts due from non-guarantor subsidiaries to the Obligor Group totaled $ 34.8 million and $ 39.6 million, respectively. </context> | us-gaap:OtherLiabilities |
(i) each share of common stock, par value $ 0.01 per share, of the Company (the “Company Common Stock”) outstanding as of immediately prior to the Effective Time (other than shares of Company Common Stock that are (A)(1) held by the Company as treasury stock; (2) held directly by Parent or Merger Sub; or (3) held by any direct or indirect wholly owned Subsidiary of Parent or Merger Sub, in each case, immediately prior to the Effective Time (collectively, the “Owned Company Shares”), (B) held by any direct or indirect wholly owned Subsidiary of the Company immediately prior to the Effective Time, (C) held by a holder who is entitled to demand, and has properly and validly demanded, appraisal for such shares of Company Common Stock in accordance with, and who complies in all respects with, Section 262 of the DGCL (“Dissenting Shares”), or (D) subject to vesting restrictions and/or forfeiture back to the Company (“Company RSAs”)) was automatically converted into the right to receive $ 63.00 per share, in cash, without interest thereon (the “Merger Consideration”); | text | 0.01 | perShareItemType | text: <entity> 0.01 </entity> <entity type> perShareItemType </entity type> <context> (i) each share of common stock, par value $ 0.01 per share, of the Company (the “Company Common Stock”) outstanding as of immediately prior to the Effective Time (other than shares of Company Common Stock that are (A)(1) held by the Company as treasury stock; (2) held directly by Parent or Merger Sub; or (3) held by any direct or indirect wholly owned Subsidiary of Parent or Merger Sub, in each case, immediately prior to the Effective Time (collectively, the “Owned Company Shares”), (B) held by any direct or indirect wholly owned Subsidiary of the Company immediately prior to the Effective Time, (C) held by a holder who is entitled to demand, and has properly and validly demanded, appraisal for such shares of Company Common Stock in accordance with, and who complies in all respects with, Section 262 of the DGCL (“Dissenting Shares”), or (D) subject to vesting restrictions and/or forfeiture back to the Company (“Company RSAs”)) was automatically converted into the right to receive $ 63.00 per share, in cash, without interest thereon (the “Merger Consideration”); </context> | us-gaap:CommonStockParOrStatedValuePerShare |
(i) each share of common stock, par value $ 0.01 per share, of the Company (the “Company Common Stock”) outstanding as of immediately prior to the Effective Time (other than shares of Company Common Stock that are (A)(1) held by the Company as treasury stock; (2) held directly by Parent or Merger Sub; or (3) held by any direct or indirect wholly owned Subsidiary of Parent or Merger Sub, in each case, immediately prior to the Effective Time (collectively, the “Owned Company Shares”), (B) held by any direct or indirect wholly owned Subsidiary of the Company immediately prior to the Effective Time, (C) held by a holder who is entitled to demand, and has properly and validly demanded, appraisal for such shares of Company Common Stock in accordance with, and who complies in all respects with, Section 262 of the DGCL (“Dissenting Shares”), or (D) subject to vesting restrictions and/or forfeiture back to the Company (“Company RSAs”)) was automatically converted into the right to receive $ 63.00 per share, in cash, without interest thereon (the “Merger Consideration”); | text | 63.00 | perShareItemType | text: <entity> 63.00 </entity> <entity type> perShareItemType </entity type> <context> (i) each share of common stock, par value $ 0.01 per share, of the Company (the “Company Common Stock”) outstanding as of immediately prior to the Effective Time (other than shares of Company Common Stock that are (A)(1) held by the Company as treasury stock; (2) held directly by Parent or Merger Sub; or (3) held by any direct or indirect wholly owned Subsidiary of Parent or Merger Sub, in each case, immediately prior to the Effective Time (collectively, the “Owned Company Shares”), (B) held by any direct or indirect wholly owned Subsidiary of the Company immediately prior to the Effective Time, (C) held by a holder who is entitled to demand, and has properly and validly demanded, appraisal for such shares of Company Common Stock in accordance with, and who complies in all respects with, Section 262 of the DGCL (“Dissenting Shares”), or (D) subject to vesting restrictions and/or forfeiture back to the Company (“Company RSAs”)) was automatically converted into the right to receive $ 63.00 per share, in cash, without interest thereon (the “Merger Consideration”); </context> | us-gaap:BusinessAcquisitionSharePrice |
The Merger Agreement further provides that, at the Effective Time, by virtue of the Merger each issued and outstanding share of common stock, par value $ 0.01 per share, of Merger Sub shall be automatically converted into and become one fully paid and non-assessable share of Surviving Corporation Stock. This resulted in 100 shares of common stock at a $ 0.01 par value per share issued and outstanding. | text | 0.01 | perShareItemType | text: <entity> 0.01 </entity> <entity type> perShareItemType </entity type> <context> The Merger Agreement further provides that, at the Effective Time, by virtue of the Merger each issued and outstanding share of common stock, par value $ 0.01 per share, of Merger Sub shall be automatically converted into and become one fully paid and non-assessable share of Surviving Corporation Stock. This resulted in 100 shares of common stock at a $ 0.01 par value per share issued and outstanding. </context> | us-gaap:CommonStockParOrStatedValuePerShare |
The Merger Agreement further provides that, at the Effective Time, by virtue of the Merger each issued and outstanding share of common stock, par value $ 0.01 per share, of Merger Sub shall be automatically converted into and become one fully paid and non-assessable share of Surviving Corporation Stock. This resulted in 100 shares of common stock at a $ 0.01 par value per share issued and outstanding. | text | 100 | sharesItemType | text: <entity> 100 </entity> <entity type> sharesItemType </entity type> <context> The Merger Agreement further provides that, at the Effective Time, by virtue of the Merger each issued and outstanding share of common stock, par value $ 0.01 per share, of Merger Sub shall be automatically converted into and become one fully paid and non-assessable share of Surviving Corporation Stock. This resulted in 100 shares of common stock at a $ 0.01 par value per share issued and outstanding. </context> | us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued |
The aggregate consideration of the Merger was approximately $ 4.9 billion, of which the Company funded $ 664.6 million. Included within these amounts is $ 53.2 million of compensation expense for the year ended December 31, 2024, related to the vesting of equity awards as of the closing of the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. | text | 4.9 | monetaryItemType | text: <entity> 4.9 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate consideration of the Merger was approximately $ 4.9 billion, of which the Company funded $ 664.6 million. Included within these amounts is $ 53.2 million of compensation expense for the year ended December 31, 2024, related to the vesting of equity awards as of the closing of the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
The aggregate consideration of the Merger was approximately $ 4.9 billion, of which the Company funded $ 664.6 million. Included within these amounts is $ 53.2 million of compensation expense for the year ended December 31, 2024, related to the vesting of equity awards as of the closing of the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. | text | 664.6 | monetaryItemType | text: <entity> 664.6 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate consideration of the Merger was approximately $ 4.9 billion, of which the Company funded $ 664.6 million. Included within these amounts is $ 53.2 million of compensation expense for the year ended December 31, 2024, related to the vesting of equity awards as of the closing of the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
The aggregate consideration of the Merger was approximately $ 4.9 billion, of which the Company funded $ 664.6 million. Included within these amounts is $ 53.2 million of compensation expense for the year ended December 31, 2024, related to the vesting of equity awards as of the closing of the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. | text | 53.2 | monetaryItemType | text: <entity> 53.2 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate consideration of the Merger was approximately $ 4.9 billion, of which the Company funded $ 664.6 million. Included within these amounts is $ 53.2 million of compensation expense for the year ended December 31, 2024, related to the vesting of equity awards as of the closing of the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
On June 13, 2024, the Company filed with the SEC a certification on Form 15, requesting the termination of registration of the shares of the Company’s 6.000 % Senior Notes due 2043 under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the all of the Company's senior notes. | text | 6.000 | percentItemType | text: <entity> 6.000 </entity> <entity type> percentItemType </entity type> <context> On June 13, 2024, the Company filed with the SEC a certification on Form 15, requesting the termination of registration of the shares of the Company’s 6.000 % Senior Notes due 2043 under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the all of the Company's senior notes. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The Company incurred $ 39.4 million of transaction costs during the year ended December 31, 2024 in connection with the Merger, which are disclosed within the Transaction costs line item within the Consolidated Statements of Operations and Comprehensive Income. There were no transaction related costs during the same period in the prior year. Further, the Company incurred $ 19.4 million of expense during the year ended December 31, 2024, related to key executives' transaction bonuses in connection with the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. | text | 39.4 | monetaryItemType | text: <entity> 39.4 </entity> <entity type> monetaryItemType </entity type> <context> The Company incurred $ 39.4 million of transaction costs during the year ended December 31, 2024 in connection with the Merger, which are disclosed within the Transaction costs line item within the Consolidated Statements of Operations and Comprehensive Income. There were no transaction related costs during the same period in the prior year. Further, the Company incurred $ 19.4 million of expense during the year ended December 31, 2024, related to key executives' transaction bonuses in connection with the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
The Company incurred $ 39.4 million of transaction costs during the year ended December 31, 2024 in connection with the Merger, which are disclosed within the Transaction costs line item within the Consolidated Statements of Operations and Comprehensive Income. There were no transaction related costs during the same period in the prior year. Further, the Company incurred $ 19.4 million of expense during the year ended December 31, 2024, related to key executives' transaction bonuses in connection with the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> The Company incurred $ 39.4 million of transaction costs during the year ended December 31, 2024 in connection with the Merger, which are disclosed within the Transaction costs line item within the Consolidated Statements of Operations and Comprehensive Income. There were no transaction related costs during the same period in the prior year. Further, the Company incurred $ 19.4 million of expense during the year ended December 31, 2024, related to key executives' transaction bonuses in connection with the Merger, which are included within the Selling, general and administrative expenses line item within the Consolidated Statements of Operations and Comprehensive Income. </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
Ventas, Inc., (together with its consolidated subsidiaries, unless otherwise indicated or except where the context otherwise requires, “we,” “us,” “our,” “Company” and other similar terms) is a real estate investment trust (“REIT”) focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. We hold a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. As of December 31, 2024, we owned or had investments in 1,387 properties consisting of 1,356 properties in our reportable business segments (“Segment Properties”) and 31 properties held by unconsolidated real estate entities in our non-segment operations. Our Company is headquartered in Chicago, Illinois with additional corporate offices in Louisville, Kentucky and New York, New York. | text | 1356 | integerItemType | text: <entity> 1356 </entity> <entity type> integerItemType </entity type> <context> Ventas, Inc., (together with its consolidated subsidiaries, unless otherwise indicated or except where the context otherwise requires, “we,” “us,” “our,” “Company” and other similar terms) is a real estate investment trust (“REIT”) focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. We hold a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. As of December 31, 2024, we owned or had investments in 1,387 properties consisting of 1,356 properties in our reportable business segments (“Segment Properties”) and 31 properties held by unconsolidated real estate entities in our non-segment operations. Our Company is headquartered in Chicago, Illinois with additional corporate offices in Louisville, Kentucky and New York, New York. </context> | us-gaap:NumberOfRealEstateProperties |
Ventas, Inc., (together with its consolidated subsidiaries, unless otherwise indicated or except where the context otherwise requires, “we,” “us,” “our,” “Company” and other similar terms) is a real estate investment trust (“REIT”) focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. We hold a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. As of December 31, 2024, we owned or had investments in 1,387 properties consisting of 1,356 properties in our reportable business segments (“Segment Properties”) and 31 properties held by unconsolidated real estate entities in our non-segment operations. Our Company is headquartered in Chicago, Illinois with additional corporate offices in Louisville, Kentucky and New York, New York. | text | 31 | integerItemType | text: <entity> 31 </entity> <entity type> integerItemType </entity type> <context> Ventas, Inc., (together with its consolidated subsidiaries, unless otherwise indicated or except where the context otherwise requires, “we,” “us,” “our,” “Company” and other similar terms) is a real estate investment trust (“REIT”) focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. We hold a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. As of December 31, 2024, we owned or had investments in 1,387 properties consisting of 1,356 properties in our reportable business segments (“Segment Properties”) and 31 properties held by unconsolidated real estate entities in our non-segment operations. Our Company is headquartered in Chicago, Illinois with additional corporate offices in Louisville, Kentucky and New York, New York. </context> | us-gaap:NumberOfRealEstateProperties |
NOI for non-segment includes management fees and promote revenues, net of expenses related to our third-party institutional private capital management platform, income from loans and investments and corporate-level expenses not directly attributable to any of our three reportable business segments. | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> NOI for non-segment includes management fees and promote revenues, net of expenses related to our third-party institutional private capital management platform, income from loans and investments and corporate-level expenses not directly attributable to any of our three reportable business segments. </context> | us-gaap:NumberOfReportableSegments |
We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. | text | 3.8 | sharesItemType | text: <entity> 3.8 </entity> <entity type> sharesItemType </entity type> <context> We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. </context> | us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding |
We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. | text | 33 | percentItemType | text: <entity> 33 </entity> <entity type> percentItemType </entity type> <context> We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest |
We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. | text | 7.7 | sharesItemType | text: <entity> 7.7 </entity> <entity type> sharesItemType </entity type> <context> We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. </context> | us-gaap:GeneralPartnersCapitalAccountUnitsOutstanding |
We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. | text | 67 | percentItemType | text: <entity> 67 </entity> <entity type> percentItemType </entity type> <context> We own a majority interest in NHP/PMB L.P. (“NHP/PMB”), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (“PMB”). Given our wholly-owned subsidiary is the general partner and the primary beneficiary of NHP/PMB, we consolidate NHP/PMB as a VIE. As of December 31, 2024, third-party investors owned 3.8 million Class A limited partnership units in NHP/PMB (“OP Units”), which represented 33 % of the total units then outstanding, and we owned 7.7 million Class B limited partnership units in NHP/PMB, representing the remaining 67 %. The OP Units may be redeemed at any time at the election of the holder for cash or, at our option, 0.9051 shares of our common stock per OP Unit, subject to adjustment in certain circumstances. We are party by assumption to a registration rights agreement with the holders of the OP Units that requires us, subject to the terms and conditions and certain exceptions set forth therein, to file and maintain a registration statement relating to the issuance of shares of our common stock upon redemption of OP Units. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest |
For certain of our research centers, we are party to contractual arrangements with TCIs that were established to enable the TCIs to receive benefits of historic tax credits (“HTCs”), new markets tax credits (“NMTCs”) or both. As of December 31, 2024 and 2023, we owned zero and one property that had syndicated NMTCs to TCIs. | text | zero | integerItemType | text: <entity> zero </entity> <entity type> integerItemType </entity type> <context> For certain of our research centers, we are party to contractual arrangements with TCIs that were established to enable the TCIs to receive benefits of historic tax credits (“HTCs”), new markets tax credits (“NMTCs”) or both. As of December 31, 2024 and 2023, we owned zero and one property that had syndicated NMTCs to TCIs. </context> | us-gaap:NumberOfRealEstateProperties |
For certain of our research centers, we are party to contractual arrangements with TCIs that were established to enable the TCIs to receive benefits of historic tax credits (“HTCs”), new markets tax credits (“NMTCs”) or both. As of December 31, 2024 and 2023, we owned zero and one property that had syndicated NMTCs to TCIs. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> For certain of our research centers, we are party to contractual arrangements with TCIs that were established to enable the TCIs to receive benefits of historic tax credits (“HTCs”), new markets tax credits (“NMTCs”) or both. As of December 31, 2024 and 2023, we owned zero and one property that had syndicated NMTCs to TCIs. </context> | us-gaap:NumberOfRealEstateProperties |
We amortize deferred financing costs, which are reported as a reduction to Senior notes payable and other debt on our Consolidated Balance Sheets, as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Amortization of approximately $ 28.9 million, $ 23.2 million and $ 18.2 million were included in Interest expense for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 28.9 | monetaryItemType | text: <entity> 28.9 </entity> <entity type> monetaryItemType </entity type> <context> We amortize deferred financing costs, which are reported as a reduction to Senior notes payable and other debt on our Consolidated Balance Sheets, as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Amortization of approximately $ 28.9 million, $ 23.2 million and $ 18.2 million were included in Interest expense for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:AmortizationOfFinancingCosts |
We amortize deferred financing costs, which are reported as a reduction to Senior notes payable and other debt on our Consolidated Balance Sheets, as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Amortization of approximately $ 28.9 million, $ 23.2 million and $ 18.2 million were included in Interest expense for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 23.2 | monetaryItemType | text: <entity> 23.2 </entity> <entity type> monetaryItemType </entity type> <context> We amortize deferred financing costs, which are reported as a reduction to Senior notes payable and other debt on our Consolidated Balance Sheets, as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Amortization of approximately $ 28.9 million, $ 23.2 million and $ 18.2 million were included in Interest expense for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:AmortizationOfFinancingCosts |
We amortize deferred financing costs, which are reported as a reduction to Senior notes payable and other debt on our Consolidated Balance Sheets, as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Amortization of approximately $ 28.9 million, $ 23.2 million and $ 18.2 million were included in Interest expense for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 18.2 | monetaryItemType | text: <entity> 18.2 </entity> <entity type> monetaryItemType </entity type> <context> We amortize deferred financing costs, which are reported as a reduction to Senior notes payable and other debt on our Consolidated Balance Sheets, as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Amortization of approximately $ 28.9 million, $ 23.2 million and $ 18.2 million were included in Interest expense for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:AmortizationOfFinancingCosts |
(“ASC 842”), we recognize rental revenue for operating lease arrangements when the tenant takes possession or controls the physical leased asset. Certain of our triple-net leases and most of our outpatient medical buildings and research centers’ (collectively, “outpatient medical and research portfolio”) leases provide for periodic and determinable increases in base rent. We recognize base rental revenues under these leases on a straight-line basis over the applicable lease term when collectability of substantially all rents is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in other assets on our Consolidated Balance Sheets. At December 31, 2024 and 2023, this cumulative excess totaled $ 202.7 million and $ 194.1 million, respectively (excluding properties classified as held for sale). | text | 202.7 | monetaryItemType | text: <entity> 202.7 </entity> <entity type> monetaryItemType </entity type> <context> (“ASC 842”), we recognize rental revenue for operating lease arrangements when the tenant takes possession or controls the physical leased asset. Certain of our triple-net leases and most of our outpatient medical buildings and research centers’ (collectively, “outpatient medical and research portfolio”) leases provide for periodic and determinable increases in base rent. We recognize base rental revenues under these leases on a straight-line basis over the applicable lease term when collectability of substantially all rents is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in other assets on our Consolidated Balance Sheets. At December 31, 2024 and 2023, this cumulative excess totaled $ 202.7 million and $ 194.1 million, respectively (excluding properties classified as held for sale). </context> | us-gaap:DeferredRentReceivablesNet |
(“ASC 842”), we recognize rental revenue for operating lease arrangements when the tenant takes possession or controls the physical leased asset. Certain of our triple-net leases and most of our outpatient medical buildings and research centers’ (collectively, “outpatient medical and research portfolio”) leases provide for periodic and determinable increases in base rent. We recognize base rental revenues under these leases on a straight-line basis over the applicable lease term when collectability of substantially all rents is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in other assets on our Consolidated Balance Sheets. At December 31, 2024 and 2023, this cumulative excess totaled $ 202.7 million and $ 194.1 million, respectively (excluding properties classified as held for sale). | text | 194.1 | monetaryItemType | text: <entity> 194.1 </entity> <entity type> monetaryItemType </entity type> <context> (“ASC 842”), we recognize rental revenue for operating lease arrangements when the tenant takes possession or controls the physical leased asset. Certain of our triple-net leases and most of our outpatient medical buildings and research centers’ (collectively, “outpatient medical and research portfolio”) leases provide for periodic and determinable increases in base rent. We recognize base rental revenues under these leases on a straight-line basis over the applicable lease term when collectability of substantially all rents is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in other assets on our Consolidated Balance Sheets. At December 31, 2024 and 2023, this cumulative excess totaled $ 202.7 million and $ 194.1 million, respectively (excluding properties classified as held for sale). </context> | us-gaap:DeferredRentReceivablesNet |
Our consolidated properties were located in 48 states, the District of Columbia, seven Canadian provinces and the United Kingdom as of December 31, 2024, with properties in one state (California) accounting for more than 10 % of our total revenues and NOI for each of the years ended December 31, 2024, 2023 and 2022. | text | 48 | integerItemType | text: <entity> 48 </entity> <entity type> integerItemType </entity type> <context> Our consolidated properties were located in 48 states, the District of Columbia, seven Canadian provinces and the United Kingdom as of December 31, 2024, with properties in one state (California) accounting for more than 10 % of our total revenues and NOI for each of the years ended December 31, 2024, 2023 and 2022. </context> | us-gaap:NumberOfStatesInWhichEntityOperates |
The 2024, 2023 and 2022 results include $ 42.0 million, $ 42.6 million and $ 42.6 million, respectively, of amortization of up-front consideration received in 2020 from a revised master lease agreement with Brookdale. | text | 42.0 | monetaryItemType | text: <entity> 42.0 </entity> <entity type> monetaryItemType </entity type> <context> The 2024, 2023 and 2022 results include $ 42.0 million, $ 42.6 million and $ 42.6 million, respectively, of amortization of up-front consideration received in 2020 from a revised master lease agreement with Brookdale. </context> | us-gaap:OtherNoncashIncomeExpense |
The 2024, 2023 and 2022 results include $ 42.0 million, $ 42.6 million and $ 42.6 million, respectively, of amortization of up-front consideration received in 2020 from a revised master lease agreement with Brookdale. | text | 42.6 | monetaryItemType | text: <entity> 42.6 </entity> <entity type> monetaryItemType </entity type> <context> The 2024, 2023 and 2022 results include $ 42.0 million, $ 42.6 million and $ 42.6 million, respectively, of amortization of up-front consideration received in 2020 from a revised master lease agreement with Brookdale. </context> | us-gaap:OtherNoncashIncomeExpense |
Results exclude nine senior housing communities which are included in our SHOP segment. | text | nine | integerItemType | text: <entity> nine </entity> <entity type> integerItemType </entity type> <context> Results exclude nine senior housing communities which are included in our SHOP segment. </context> | us-gaap:NumberOfRealEstateProperties |
Results exclude 19 outpatient medical buildings included in “All others.” | text | 19 | integerItemType | text: <entity> 19 </entity> <entity type> integerItemType </entity type> <context> Results exclude 19 outpatient medical buildings included in “All others.” </context> | us-gaap:NumberOfRealEstateProperties |
2025 minimum lease payments include all assets covered by the Brookdale lease as of December 31, 2024, of which $ 86.5 million is associated with 56 senior housing properties for which the lease will expire on December 31, 2025. | text | 86.5 | monetaryItemType | text: <entity> 86.5 </entity> <entity type> monetaryItemType </entity type> <context> 2025 minimum lease payments include all assets covered by the Brookdale lease as of December 31, 2024, of which $ 86.5 million is associated with 56 senior housing properties for which the lease will expire on December 31, 2025. </context> | us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths |
2025 minimum lease payments include all assets covered by the Brookdale lease as of December 31, 2024, of which $ 86.5 million is associated with 56 senior housing properties for which the lease will expire on December 31, 2025. | text | 56 | integerItemType | text: <entity> 56 </entity> <entity type> integerItemType </entity type> <context> 2025 minimum lease payments include all assets covered by the Brookdale lease as of December 31, 2024, of which $ 86.5 million is associated with 56 senior housing properties for which the lease will expire on December 31, 2025. </context> | us-gaap:NumberOfRealEstateProperties |
In January 2025, we acquired two senior housing communities reported within our SHOP segment for an aggregate purchase price of $ 70.0 million. | text | 70.0 | monetaryItemType | text: <entity> 70.0 </entity> <entity type> monetaryItemType </entity type> <context> In January 2025, we acquired two senior housing communities reported within our SHOP segment for an aggregate purchase price of $ 70.0 million. </context> | us-gaap:AssetAcquisitionConsiderationTransferred |
During the year ended December 31, 2024, we acquired 50 senior housing communities reported within our SHOP segment and five long-term acute care facilities (“LTACs”) reported within our NNN segment for an aggregate purchase price of $ 1.9 billion. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, we acquired 50 senior housing communities reported within our SHOP segment and five long-term acute care facilities (“LTACs”) reported within our NNN segment for an aggregate purchase price of $ 1.9 billion. </context> | us-gaap:AssetAcquisitionConsiderationTransferred |
During the year ended December 31, 2022, for an aggregate purchase price of $ 453.2 million, we acquired 18 outpatient medical buildings leased to affiliates of Ardent, one behavioral health center, one research center (all of which are reported within our OM&R segment) and two senior housing communities (which are reported within our SHOP segment). | text | 453.2 | monetaryItemType | text: <entity> 453.2 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, for an aggregate purchase price of $ 453.2 million, we acquired 18 outpatient medical buildings leased to affiliates of Ardent, one behavioral health center, one research center (all of which are reported within our OM&R segment) and two senior housing communities (which are reported within our SHOP segment). </context> | us-gaap:AssetAcquisitionConsiderationTransferred |
During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. | text | 19 | integerItemType | text: <entity> 19 </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. | text | 12 | integerItemType | text: <entity> 12 </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. | text | 24 | integerItemType | text: <entity> 24 </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. | text | 315.1 | monetaryItemType | text: <entity> 315.1 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, we sold 19 senior housing communities in our SHOP segment, 12 outpatient medical buildings ( one of which was vacant) in our OM&R segment and 24 properties in our NNN segment for aggregate consideration of $ 315.1 million and recognized $ 57.0 million in Gain on real estate dispositions in our Consolidated Statements of Income. </context> | us-gaap:ProceedsFromSaleOfRealEstateHeldforinvestment |
During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. | text | seven | integerItemType | text: <entity> seven </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. | text | 10 | integerItemType | text: <entity> 10 </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. | text | nine | integerItemType | text: <entity> nine </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. | text | 399.5 | monetaryItemType | text: <entity> 399.5 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, we sold seven communities in our SHOP segment, 10 properties in our OM&R segment, nine properties in our NNN segment and two land parcels for aggregate consideration of $ 399.5 million and recognized a gain on the sale of these assets of $ 62.1 million in our Consolidated Statements of Income. </context> | us-gaap:ProceedsFromSaleOfRealEstateHeldforinvestment |
During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. | text | seven | integerItemType | text: <entity> seven </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. | text | 115.1 | monetaryItemType | text: <entity> 115.1 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. </context> | us-gaap:ProceedsFromSaleOfRealEstateHeldforinvestment |
During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. | text | 7.8 | monetaryItemType | text: <entity> 7.8 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, we sold seven communities in our SHOP segment, two properties in our OM&R segment, three properties in our NNN segment, two vacant properties for aggregate consideration of $ 115.1 million and recognized a net gain on the sale of these assets of $ 7.8 million in our Consolidated Statements of Income. </context> | us-gaap:GainLossOnDispositionOfAssets1 |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 86.0 | monetaryItemType | text: <entity> 86.0 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 43.8 | monetaryItemType | text: <entity> 43.8 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 40.7 | monetaryItemType | text: <entity> 40.7 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 226.6 | monetaryItemType | text: <entity> 226.6 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 190.5 | monetaryItemType | text: <entity> 190.5 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 19.2 | monetaryItemType | text: <entity> 19.2 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 16.9 | monetaryItemType | text: <entity> 16.9 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 107.8 | monetaryItemType | text: <entity> 107.8 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 76.4 | monetaryItemType | text: <entity> 76.4 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 27.5 | monetaryItemType | text: <entity> 27.5 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, we recognized impairments of $ 86.0 million comprising of $ 43.8 million, $ 1.5 million and $ 40.7 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2023, we recognized impairments of $ 226.6 million comprising of $ 190.5 million, $ 19.2 million and $ 16.9 million impairments in our SHOP, OM&R and NNN segments, respectively. For the year ended December 31, 2022, we recognized impairments of $ 107.8 million comprising of $ 76.4 million, $ 27.5 million and $ 3.9 million impairments in our SHOP, OM&R and NNN segments, respectively. The impairments are recorded primarily as a component of Depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the future cash flows of the impaired assets. </context> | us-gaap:ImpairmentOfRealEstate |
In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. | text | 109.0 | monetaryItemType | text: <entity> 109.0 </entity> <entity type> monetaryItemType </entity type> <context> In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. </context> | us-gaap:DebtInstrumentFaceAmount |
In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. | text | 4.50 | percentItemType | text: <entity> 4.50 </entity> <entity type> percentItemType </entity type> <context> In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. | text | 5.75 | percentItemType | text: <entity> 5.75 </entity> <entity type> percentItemType </entity type> <context> In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. | text | 6.00 | percentItemType | text: <entity> 6.00 </entity> <entity type> percentItemType </entity type> <context> In September 2024, we provided new secured debt financing of $ 109.0 million to the owner of a senior housing property, secured by the asset and with additional credit support. The loan provides us with a right of first offer to purchase the asset on certain terms and conditions. The loan has a 3-year term and bears interest at a variable rate based on one-month SOFR, subject to a floor of 4.50 %, plus a spread of 5.75 %, increasing to 6.00 % commencing October 1, 2025. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On May 1, 2023, we took ownership of the properties that secured the Company’s cash-pay non-recourse mezzanine loan to Santerre Health Investors (the “Santerre Mezzanine Loan”) by converting the outstanding principal amount of the Santerre Mezzanine Loan to equity, with no additional consideration being paid. As a result, the Santerre Mezzanine Loan is no longer outstanding. The properties consisted of a diverse pool of outpatient medical buildings, senior housing communities, triple-net leased skilled nursing facilities and hospital assets in the United States, which, at the time, also secured a $ 1 billion non-recourse senior mortgage loan issued under the CHC Commercial Mortgage Trust 2019-CHC (the “CHC Mortgage Loan”). For additional information regarding the CHC Mortgage Loan, see “Note 10 – Senior Notes Payable and Other Debt.” | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> On May 1, 2023, we took ownership of the properties that secured the Company’s cash-pay non-recourse mezzanine loan to Santerre Health Investors (the “Santerre Mezzanine Loan”) by converting the outstanding principal amount of the Santerre Mezzanine Loan to equity, with no additional consideration being paid. As a result, the Santerre Mezzanine Loan is no longer outstanding. The properties consisted of a diverse pool of outpatient medical buildings, senior housing communities, triple-net leased skilled nursing facilities and hospital assets in the United States, which, at the time, also secured a $ 1 billion non-recourse senior mortgage loan issued under the CHC Commercial Mortgage Trust 2019-CHC (the “CHC Mortgage Loan”). For additional information regarding the CHC Mortgage Loan, see “Note 10 – Senior Notes Payable and Other Debt.” </context> | us-gaap:DebtInstrumentFaceAmount |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.